Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy

British Journal of Cancer

Volumn 76, Issue 7, 1997, Pages 852-854

  Kelsey, K T ^a   Ross, D ^b   Traver, R D ^b   Christiani, D C ^a,c   Zuo, Z F ^a   Spitz, M R ^d   Wang, M ^e   Xu, X ^a   Lee, B K ^f   Schwartz, B S ^g   Wiencke, J K ^h  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e WANNAN MEDICAL COLLEGE   (China)

^f Soonchunhyang University   (South Korea)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DT diaphorase; Ethnicity; NQ01; Polymorphism; Second cancer

Indexed keywords

DRUG METABOLIZING ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; CANCER CHEMOTHERAPY; DNA POLYMORPHISM; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 9844256095     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.474     Document Type: Article

References (18)

1. Berenberg JL (1991) Response to treatment of breast cancer. Breast Cancer Res Treat Suppl. 1: S147-155
2. Elledge RM, Clark GM, Chamness GC and Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among White, Hispanic and Black women in the United Stales. J Natl Cancer Inst 86: 705-712
3. Fitzsimmons SA, Workman P, Grever M, Paul K, Camalier R and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor Cell Line Panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269
4. Modiano MR, Villar-Werstler P, Meister P and Figueroa-Valles N (1995) Cancer in Hispanics: issues of concern. J Natl Cancer Inst Monogr 18: 35-39
5. Paul K, Camalier R, Fitzsimmons SA, Lewis AD, Workman P and Grever M (1994) Correlation of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel. Proc Am Assoc Cancer Res 35: 369
6. Philpott NJ, Bevan DH and Gordon-Smith EC (1993) Secondary leukemia after MMM combined modality therapy for breast carcinoma. Lancet 341: 1289
7. Platz EA, Nelson HH and Kelsey KT (1997) Second cancers. In Cancer Medicine, Vol 1, 4th edn Holland JF, Frei E, Bast R, Kufe D, Morton D and Weichselbaum R (eds), 3283-3300. Lea & Febiger: Philadelphia
8. Riley RJ and Workman P (1992) DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43: 1657-1669
9. Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT and Gibson NW (1993) DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metast Rev 12: 83-101
10. Ross D, Beall H, Traver RD, Siegel D, Phillips RM and Gibson NW (1994) Bioactivation of quinones by DT-diaphorase. Molecular, biochemical and chemical studies. Oncol Res 6: 493-500
11. Ross D, Beall HD, Siegel D, Traver RD and Gustafson DL (1996a) Enzymology of bioreductive drug activation. Br J Cancer 74 (suppl xxvii ): 51-58
12. Ross D, Traver RD, Siegel D, Kuehl BL, Misra V and Rauth AM (1996b) A polymorphism in NAD(P)H: quinone oxidoreductase (NQO1). Relationship of a homozygous mutation at position 609 of the NQOI cDNA to NQOI activity. Br J Cancer 74: 995-996
13. Rosvold EA, McGlynn KA, Lustbader ED and Beutow KH (1995) Re: Detection of a point mutation in NQO1 (DT diaphorase) in a patient with colon cancer (letter). J Natl Cancer Inst 87: 1802-1803
14. Rothman N, Traver RD, Smith MT, Hayes RB, Li G-L, Campleman S, Dosemeci M, Zhang L, Linet M, Wacholder S, Yin S-N and Ross D (1996) Lack of NAD(P) H: quinone oxidoreductase activity (NQO1) is associated with increased risk of benzene hematotoxicity. Proc Am Assoc Cancer Res 37: 258
15. Siegel D, Gibson NW, Preusch PC and Ross D (1990) Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483-7489
16. Traver RD, Horikoshi T, Danenherg KD, Stadbauer TH, Danenberg PV, Ross D and Gibson NW (1992) NAD(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52: 797-802
17. Walton MI, Smith PJ and Workman P (1991) The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 3: 199-206
18. Workman P (1994) Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6: 461-475